WO2023183295A1 - Dispositifs et systèmes destinés à mettre en œuvre des traitements thérapeutiques de lumière - Google Patents

Dispositifs et systèmes destinés à mettre en œuvre des traitements thérapeutiques de lumière Download PDF

Info

Publication number
WO2023183295A1
WO2023183295A1 PCT/US2023/015757 US2023015757W WO2023183295A1 WO 2023183295 A1 WO2023183295 A1 WO 2023183295A1 US 2023015757 W US2023015757 W US 2023015757W WO 2023183295 A1 WO2023183295 A1 WO 2023183295A1
Authority
WO
WIPO (PCT)
Prior art keywords
information
light
server
treatment
illumination device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/015757
Other languages
English (en)
Inventor
F. Neal Hunter
John A. DEMOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Know Bio LLC
Original Assignee
Know Bio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/656,141 external-priority patent/US20220212031A1/en
Application filed by Know Bio LLC filed Critical Know Bio LLC
Publication of WO2023183295A1 publication Critical patent/WO2023183295A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N2005/0612—Apparatus for use inside the body using probes penetrating tissue; interstitial probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0644—Handheld applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0645—Applicators worn by the patient
    • A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head

Definitions

  • the present disclosure relates generally to devices and systems for impinging light on tissue to induce one or more biological effects and, more particularly, to illumination devices and related systems for implementing therapeutic treatments of light.
  • Phototherapy involves exposure of the body to light to induce biological effects and promote various health-related medical benefits. Advancements in therapeutic light treatments have demonstrated beneficial results for inactivating and/or reducing viral loads of infectious diseases. Phototherapeutic light treatments have also demonstrated other health-related benefits, including the promotion of hair growth, treatment of skin or tissue inflammation such as acne, promoting tissue or skin healing or rejuvenation, enhancing wound healing, pain management, reduction of wrinkles, scars, stretch marks, varicose veins, and spider veins, treating cardiovascular disease, treating erectile dysfunction, treating microbial infections, treating hyperbilirubinemia, and treating various oncological and non-oncological diseases and disorders including diseases induced by human papillomavirus (HPV).
  • HPV human papillomavirus
  • Various mechanisms by which phototherapy has been suggested to provide therapeutic benefits include inactivating and inhibiting growth of microorganisms and pathogens, increasing circulation (e.g., by increasing the formation of new capillaries), stimulating the production of collagen, stimulating the release of adenosine triphosphate (ATP), enhancing porphyrin production, reducing excitability of nervous system tissues, modulating fibroblast activity, increasing phagocytosis, inducing thermal effects, stimulating tissue granulation and connective tissue phagocytosis, reducing inflammation, and stimulating acetylcholine release.
  • increasing circulation e.g., by increasing the formation of new capillaries
  • stimulating the production of collagen stimulates the release of adenosine triphosphate (ATP), enhancing porphyrin production, reducing excitability of nervous system tissues, modulating fibroblast activity, increasing phagocytosis, inducing thermal effects, stimulating tissue granulation and connective tissue phagocytosis, reducing inflammation, and stimulating acetylcholine
  • Phototherapy has also been suggested to stimulate cells to produce nitric oxide, which may act as a signaling messenger, cytotoxin, antiapoptotic agent, antioxidant, and regulator of microcirculation.
  • Nitric oxide is recognized to relax vasculature smooth muscles, dilate blood vessels, inhibit aggregation of platelets, and modulate T-cell mediated immune response.
  • phototherapy shows promise for improving health and/or treating myriad medical conditions.
  • the present disclosure relates generally to devices and systems for impinging light on tissue to induce one or more biological effects and, more particularly, to illumination devices and related systems for implementing therapeutic treatments of light.
  • Systems may include illumination devices that are configured to provide phototherapy for a variety of medical indications and/or health-related benefits. Illumination devices may be connected to systems that administer and/or monitor multiple illumination devices across multiple geographic regions to compile regional and/or global information related to phototherapeutic usage. Certain aspects relate to system elements, such as local devices and/or servers that are capable of generating treatment protocols for illumination devices based on diagnostic information. After treatment protocols are implemented by illumination devices, administered treatment information along with location information may be provided to the local devices and/or servers.
  • an illumination device for phototherapeutic delivery of light comprises; a light source; a communication interface; and a control system associated with the communication interface, the control system configured to a collect diagnostic information, implement a treatment protocol, and send the diagnostic information and administered light treatment information associated with implementing the treatment protocol to a server via the communication interface.
  • the illumination device may further comprise one or more of a sensor and a camera associated with the control system, the one or more of the sensor and the camera being configured to collect at least a portion of the diagnostic information.
  • the control system is configured with a preconfigured treatment protocol, and the treatment protocol is modified from the pre-configured treatment protocol based on the diagnostic information.
  • control system is configured to determine the treatment protocol based on the diagnostic information. In certain embodiments, the control system is further configured to receive the treatment protocol from the server based on the diagnostic information. In certain embodiments, the control system is further configured to determine location information associated with the administered light treatment information and send the location information to the server.
  • an illumination device for phototherapeutic delivery of light comprises; a light source; a communication interface; and a control system associated with the communication interface, the control system configured to implement a treatment protocol, determine location information associated with the treatment protocol, and send the location information to a server via the communication interface.
  • the location information comprises a global positioning system (GPS) location.
  • the control system is further configured to: collect diagnostic information; send the diagnostic information to the server; and receive the treatment protocol from the server and control the light source to implement the treatment protocol.
  • the control system is further configured to send the diagnostic information to a local device before sending the diagnostic information to the server.
  • control system is further configured to determine the location information before sending the diagnostic information to the server. In certain embodiments, the control system is further configured to determine the location information after receiving the treatment protocol from the server. In certain embodiments, at least one of the location information, the diagnostic information, and the treatment protocol comprises encrypted data. In certain embodiments, the treatment protocol comprises a pre-configured treatment protocol that is associated with the control system. In certain embodiments, the control system is further configured to receive the treatment protocol from a local device that is in communication with the control system and the server. In certain embodiments, the control system is further configured to send administered light treatment information to the server, the administered light treatment information comprising one or more of a wavelength of light and a dose of light associated with administered light treatment.
  • a system for phototherapeutic delivery of light comprises; a server; and a server-side application associated with the server, the server-side application configured to: receive diagnostic information from at least one of an illumination device and a local device that is in communication with the illumination device; generate a treatment protocol based on the diagnostic information; send the treatment protocol to the illumination device; and receive location information associated with administered light treatment information after the treatment protocol is implemented by the illumination device.
  • the server-side application is configured to compile geospatial information based on: a plurality of treatment protocols generated for a plurality of illumination devices; and location information associated with administered light treatment information received from the plurality of illumination devices.
  • the server-side application is further configured to receive additional user information together with the diagnostic information, the additional user information comprising one or more of a medical history and demographics of a user. In certain embodiments, the server-side application is configured to associate additional user information with the diagnostic information, the additional user information comprising one or more of a medical history and demographics of a user. In certain embodiments, one or more of the diagnostic information, the treatment protocol, and the location information comprises encrypted data. In certain embodiments, the server comprises an artificial intelligence library that is used to generate the treatment protocol based on the diagnostic information. In certain embodiments, the administered light treatment information comprises one or more of a wavelength of light and a dose of light implemented by the illumination device.
  • a system for phototherapeutic delivery of light comprises; a server; and a server-side application associated with the server, the server-side application configured to: receive administered light treatment information from a plurality of illumination devices, the administered light treatment information being associated with location information; and provide data for compiling geospatial information based on the administered light treatment information and the location information.
  • the administered light treatment information comprises one or more of a wavelength of light and a dose of light associated with administered light treatments implemented by the plurality of illumination devices.
  • the administered light treatment information is associated with one or more of a user’s diagnostic information, medical history, and demographics.
  • the server-side application is further configured to receive the administered light treatment information from a local device that is in communication with the plurality of illumination devices.
  • the administered light treatment information comprises encrypted data.
  • any of the foregoing aspects individually or together, and/or various separate aspects and features as described herein, may be combined for additional advantage. Any of the various features and elements as disclosed herein may be combined with one or more other disclosed features and elements unless indicated to the contrary herein.
  • FIG. 1 is a schematic view of a system for administering and monitoring phototherapy treatments of multiple illumination devices at various geographic locations.
  • FIG. 2 is a schematic view of the system of FIG. 1 with further details provided for one of the illumination devices.
  • FIG. 3 is a call-flow diagram illustrating an implementation of the system of FIGS. 1 and 2 where a server determines a treatment protocol for the illumination device based on received diagnostic and/or user information from the illumination device and/or a local device.
  • FIG. 4 is a call-flow diagram illustrating another implementation of the system of FIGS. 1 and 2 where the local device determines a treatment protocol for the illumination device and implemented treatment and location information is sent to the server.
  • FIG. 5 is a call-flow diagram illustrating another implementation of the system of FIGS. 1 and 2 where the local device collects diagnostic information and associates the diagnostic information with a user ID independently from the illumination device.
  • FIG. 6 is a call-flow diagram illustrating another implementation of the system of FIGS. 1 and 2 where the illumination device is pre-configured with one or more treatment protocols that may be implemented.
  • FIG. 7 A is a perspective view of an exemplary illumination device that is configured to direct light emissions within or through a body cavity, such as an oral cavity.
  • FIG. 7B is a side view of the illumination device of FIG. 7A.
  • FIG. 8A is an exploded view of an illumination device embodied as a wearable cap for delivering phototherapy to a scalp and/or brain of a user.
  • FIG. 8B is a bottom plan view of a flexible printed circuit board (FPCB) from the illumination device of FIG. 8A illustrating light emitters and standoffs arranged thereon.
  • FPCB flexible printed circuit board
  • FIG. 9 is an illustration representing a continuous glucose monitor (CGM) with an incorporated light source capable of delivering foreign body response (FBR)-modulating light to a host's skin during monitoring.
  • CGM continuous glucose monitor
  • FBR foreign body response
  • FIG. 10 is an illustration representing a CGM that is similar to the CGM of FIG. 9 and further includes a corresponding light delivery structure capable of delivering FBR-modulating light beneath the host's skin during monitoring.
  • Relative terms such as “below” or “above” or “upper” or “lower” or “horizontal” or “vertical” may be used herein to describe a relationship of one element, layer, or region to another element, layer, or region as illustrated in the Figures. It will be understood that these terms and those discussed above are intended to encompass different orientations of the device in addition to the orientation depicted in the Figures.
  • Embodiments are described herein with reference to schematic illustrations of embodiments of the disclosure. As such, the actual dimensions of the layers and elements can be different, and variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are expected. For example, a region illustrated or described as square or rectangular can have rounded or curved features, and regions shown as straight lines may have some irregularity. Thus, the regions illustrated in the figures are schematic and their shapes are not intended to illustrate the precise shape of a region of a device and are not intended to limit the scope of the disclosure.
  • the present disclosure relates generally to devices and systems for impinging light on tissue to induce one or more biological effects and, more particularly, to illumination devices and related systems for implementing therapeutic treatments of light.
  • Systems may include illumination devices that are configured to provide phototherapy for a variety of medical indications and/or health-related benefits. Illumination devices may be connected to systems that administer and/or monitor multiple illumination devices across multiple geographic regions to compile regional and/or global information related to phototherapeutic usage. Certain aspects relate to system elements, such as local devices and/or servers that are capable of generating treatment protocols for illumination devices based on diagnostic information. After treatment protocols are implemented by illumination devices, administered light treatment information along with location information may be provided to the local devices and/or servers.
  • Light, or phototherapeutic light may be administered at one or more wavelengths with one or more corresponding doses to induce one or more biological effects for recipient tissue.
  • Biological effects may include at least one of inactivating and inhibiting growth of one or more combinations of microorganisms and pathogens, including but not limited to viruses, bacteria, fungi, and other microbes, among others.
  • Biological effects may also include one or more of upregulating and/or downregulating a local immune response, stimulating enzymatic generation of nitric oxide to increase endogenous stores of nitric oxide, releasing nitric oxide from endogenous stores of nitric oxide, inducing an anti-inflammatory effect, promoting increased blood flow in the brain for the treatment of dementia, promotion of hair growth, and/or modulation of foreign body responses (FBR) in tissues.
  • light may be referred to as nitric oxide modulating light to increase concentrations of unbound nitric oxide within living tissue.
  • Light may also be administered at one or more wavelengths as a pre-exposure prophylaxis or a post-exposure prophylaxis in order to eliminate pathogens in or on tissue of the upper respiratory tract and/or amplify host defense systems.
  • Embodiments of the present disclosure may be used to prevent and/or treat respiratory infections and other infectious diseases.
  • Wavelengths of light may be selected based on at least one intended biological effect for one or more of the targeted tissues and the targeted microorganisms and/or pathogens.
  • wavelengths of light may include visible light in any number of wavelength ranges based on the intended biological effect. Further aspects involve light impingement on tissue for multiple microorganisms and/or multiple pathogenic biological effects, either with light of a single peak wavelength or a combination of light with more than one peak wavelength.
  • Devices and methods for light treatments include those that provide light doses for inducing biological effects on various targeted pathogens and targeted tissues with increased efficacy and reduced cytotoxicity.
  • Light doses may include various combinations of irradiances, wavelengths, and exposure times, and such light doses may be administered continuously or discontinuously with a number of pulsed exposures.
  • Certain aspects of the present disclosure generally relate to devices and related systems for promoting various health-related benefits, such as treating, preventing, and/or reducing the biological activity of pathogens while they are in one or more areas of the body.
  • related devices and methods may prevent or reduce infections by reducing microbial load, decreasing the ability for penetration into cells at the site of infection, and amplifying host defense systems, all of which may minimize or avoid the need for traditional antimicrobial medicines.
  • related devices and methods for light irradiation of tissues may be provided to supplement and/or enhance the effects of traditional antimicrobial medicines.
  • phototherapy relates to the therapeutic use of light.
  • phototherapy may be used to promote various health-related benefits.
  • the mechanisms by which certain wavelengths of light are effective can vary, depending on the wavelength that is administered and the targeted biological effect.
  • Biological effects, including antimicrobial effects, can be induced over a wide range of wavelengths, including ultraviolet (UV) ranges, visible light ranges, and infrared (IR) ranges, and combinations thereof.
  • UV ultraviolet
  • IR infrared
  • Various wavelengths of visible light may be irradiated on human tissue with little or no impact on tissue viability.
  • various wavelengths of visible light may elicit antimicrobial and/or anti-pathogenic behavior in corresponding tissues, including any of the aforementioned biological effects.
  • light with a peak wavelength in a range from 400 nanometers (nm) to 450 nm may inactivate microorganisms that are in a cell-free environment and/or inhibit replication of microorganisms that are in a cell- associated environment and/or stimulate enzymatic generation of nitric oxide, while also upregulating a local immune response in target tissue.
  • light with a peak wavelength in a range from 400 nm to 450 nm may be well suited for fighting invading viral and/or bacterial pathogens and corresponding diseases that may originate in the respiratory tract, including Orthomyxoviridae (e.g., influenza), common colds, coronavirida (e.g., coronavirus), picornavirus infections, tuberculosis, pneumonia, bronchitis, and sinusitis.
  • NIR near-infrared
  • Anti-inflammatory effects may be useful in treating disorders, particularly microbial disorders that result in inflammation along the respiratory tract.
  • red light may be used as part of treatment protocols that reduce any tissue inflammation that may result from exposure to blue light, which may positively impact cell viability, thereby lowering cytotoxicity even further.
  • a decrease in inflammation can be beneficial when treating viral infections, particularly when a virus can elicit a cytokine storm and/or inflammation can result in secondary bacterial infections.
  • the combination of blue light, such as light at around 425 nm, and red light at one or more anti-inflammatory wavelengths can provide a desirable combination of biological effects.
  • UV light e.g., UV-A light having a peak wavelength in a range of from 315 nm to 400 nm, UV-B light having a peak wavelength in a range of from 280 nm to 315 nm, and UV-C light having a peak wavelength in a range from 200 nm to 280 nm
  • UV-A light having a peak wavelength in a range of from 315 nm to 400 nm
  • UV-B light having a peak wavelength in a range of from 280 nm to 315 nm
  • UV-C light having a peak wavelength in a range from 200 nm to 280 nm
  • overexposure to UV light may lead to cytotoxicity concerns in associated tissue.
  • UV light with a peak wavelength in a range from 385 nm to 450 nm may be provided to elicit an antimicrobial and/or anti-pathogenic effect.
  • such wavelengths of light may be used in treatment protocols that also administer antiinflammatory light.
  • Doses of light to induce one or more biological effects may be administered with one or more light characteristics, including peak wavelengths, radiant flux, and irradiance to target tissues.
  • Irradiances to target tissues may be provided in a range from 0.1 milliwatts per square centimeter (mW/cm 2 ) to 200 mW/cm 2 , or in a range from 5 mW/cm 2 to 200 mW/cm 2 , or in a range from 5 mW/cm 2 to 100 mW/cm 2 , or in a range from 5 mW/cm 2 to 60 mW/cm 2 , or in a range from 60 mW/cm 2 to 100 mW/cm 2 , or in a range from 100 mW/cm 2 to 200 mW/cm 2 .
  • Such irradiance ranges may be administered in one or more of continuous wave and pulsed configurations, including light-emitting diode (LED)- based photonic devices that are configured with suitable power (radiant flux) to irradiate a target tissue with any of the above-described ranges.
  • LED light-emitting diode
  • a light source for providing such irradiance ranges may be configured to provide radiant flux values from the light source of at least 5 mW, or at least 10 mW, or at least 15 mW, or at least 20 mW, or at least 30 mW, or at least 40 mW, or at least 50 mW, or at least 100 mW, or at least 200 mW, or in a range of from 5 mW to 200 mW, or in a range of from 5 mW to 100 mW, or in a range of from 5 mW to 60 mW, or in a range of from 5 mW to 30 mW, or in a range of from 5 mW to 20 mW, or in a range of from 5 mW to 10 mW, or in a range of from 10 mW to 60 mW, or in a range of from 20 mW to 60 mW, or in a range of from 30 mW to 60 mW, or in a
  • pulsed irradiances of light may be administered, thereby allowing safe application of significantly higher irradiances.
  • Pulsed irradiances may be characterized as average irradiances that fall within safe ranges, thereby providing no or minimal damage to the applied tissue.
  • irradiances in a range from 0.1 W/cm 2 to 10 W/cm 2 may be safely pulsed to target tissue.
  • Administered doses of light may be referred to as therapeutic doses of light in certain aspects.
  • Doses of light may include various suitable combinations of the peak wavelength, the irradiance to the target tissue, and the exposure time period. Particular doses of light are disclosed that are tailored to provide safe and effective light for inducing one or more biological effects for various types of pathogens and corresponding tissue types.
  • the dose of light may be administered within a single time period in a continuous or a pulsed manner.
  • a dose of light may be repeatably administered a number of times to provide a cumulative or total dose over a cumulative time period.
  • a single dose of light as disclosed herein may be provided over a single time period, such as in a range from 10 microseconds to no more than an hour, or in a range from 10 seconds to no more than an hour, while the single dose may be repeated at least twice to provide a cumulative dose over a cumulative time period, such as a 24-hour time period.
  • doses of light are described that may be provided in a range from 0.5 joules per square centimeter (J/cm 2 ) to 100 J/cm 2 , or in a range from 0.5 J/cm 2 to 50 J/cm 2 , or in a range from 2 J/cm 2 to 80 J/cm 2 , or in a range from 5 J/cm 2 to 50 J/cm 2 , while corresponding cumulative doses may be provided in a range from 1 J/cm 2 to 1000 J/cm 2 , or in a range from 1 J/cm 2 to 500 J/cm 2 , or in a range from 1 J/cm 2 to 200 J/cm 2 , or in a range from 1 J/cm 2 to 100 J/cm 2 , or in a range from 4 J/cm 2 to 160 J/cm 2 , or in a range from 10 J/cm 2 to 100 J/cm 2 , among other disclosed ranges.
  • a single dose may be administered in a range from 10 J/cm 2 to 20 J/cm 2 , and the single dose may be repeated twice a day for four consecutive days to provide a cumulative dose in a range from 80 J/cm 2 to 160 J/cm 2 .
  • a single dose may be administered at about 30 J/cm 2 , and the single dose may be repeated twice a day for seven consecutive days to provide a cumulative dose of 420 J/cm 2 .
  • light for inducing one or more biological effects may include administering different doses of light to a target tissue to induce one or more biological effects for different target pathogens.
  • light doses as disclosed herein may provide non-systemic and durable effects to targeted tissues.
  • Light can be applied locally and without off-target tissue effects or overall systemic effects associated with conventional drug therapies which can spread throughout the body.
  • phototherapy may induce a biological effect and/or response in a target tissue without triggering the same or other biological responses in other parts of the body.
  • Phototherapy as described herein may be administered with safe and effective doses that are durable. For example, a dose may be applied for minutes at a time, one to a few times a day, and the beneficial effect of the phototherapy may continue in between treatments.
  • Light sources may provide coherent light or incoherent light and may include one or more of LEDs, organic LEDs (OLEDs), lasers, and other lamps according to aspects of the present disclosure.
  • Lasers may be used for irradiation in combination with optical fibers or other delivery mechanisms.
  • LEDs are solid state electronic devices capable of emitting light when electrically activated. LEDs may be configured across many different targeted emission spectrum bands with high efficiency and relatively low costs. Accordingly, LEDs may be used as light sources in photonic devices for phototherapy applications. Light from an LED is administered using a device capable of delivering the requisite power to a targeted treatment area or tissue. High power LED-based devices can be employed to fulfill various spectral and power needs for a variety of different medical applications.
  • LED-based photonic devices described herein may be configured with suitable power to provide irradiances as high as 100 mW/cm 2 or 200 mW/cm 2 in the desired wavelength range.
  • An LED array in this device can be incorporated into an irradiation head, a hand piece, and/or as an external unit.
  • a directed energy source may include any of the various light sources previously described and/or an energy source capable of providing one or more of heat, IR heating, resistance heating, radio waves, microwaves, soundwaves, ultrasound waves, electromagnetic interference, electromagnetic radiation, and direct electrical stimulation that may be directed to a target body tissue.
  • Combinations of visual and non-visual electromagnetic radiation may include peak wavelengths in a range from 180 nm to 4000 nm.
  • Illumination devices as disclosed herein may include a light source and another directed energy source capable of providing directed energy beyond visible and UV light. In other embodiments, the other directed energy source capable of providing directed energy beyond visible and UV light may be provided separately from illumination devices of the present disclosure.
  • Illumination devices include any devices configured to provide light therapy for promoting various health-related benefits.
  • Exemplary illumination devices include those that are configured to prevent and/or treat infectious diseases (usable to stimulate an immune response to prevent infections, reduce the presence of pathogens, etc.), stimulate growth of hair, promote increased blood flow in the brain for the treatment of dementia, and/or modulate foreign body responses in tissue.
  • an illumination device may embody a device that is configured to direct light emissions within or through a body cavity, such as the oral cavity, to provide light treatments for upper respiratory infections.
  • exemplary illumination devices may embody devices configured to provide light therapy to the scalp to promote hair growth or to provide light therapy to blood vessels associated with the brain.
  • exemplary illumination device may embody devices with probes and/or needles that remain in tissue for periods of time, such as continuous glucose monitors.
  • Further devices may include lung light devices for delivering therapeutic doses to the lung for lower respiratory infections.
  • illumination devices for providing phototherapy may embody connected devices that are part of larger systems that administer and/or monitor light treatment protocols across multiple illumination devices in one or more geographic locations.
  • treatment protocols may also be referred to as light treatment protocols or phototherapy protocols.
  • Treatment protocols may include one or more wavelengths of light with corresponding dosing protocols that are intended to provide various biological effects.
  • such systems may include one or more servers that are able to communicate with individual illumination devices by way of one or more networks.
  • one or more local devices may serve as intermediate devices in communication with both the server and the individual illumination devices. In this manner, systems as described herein may allow monitoring of various phototherapy treatment protocols that are being administered in different geographic locations.
  • the ability to compile geospatial information as illumination devices are being used may be beneficial in the early identification of infectious disease outbreaks. Notably, early detection may enable earlier implementation of safety measures in identified outbreak regions in order reduce outbreak severities. Additionally, when implemented phototherapy treatments in an outbreak region start to decline, the compiled geospatial information may enhance accuracy in determining when outbreaks are subsiding. In the context of other types of illumination devices, such as those that provide light therapy for hair growth or those that are used in tandem with other devices, such as continuous glucose monitoring, compiled geospatial information may provide other benefits, such as differentiating real-time health and/or wellness activities by geographic region.
  • illumination devices and/or overall systems as described and/or illustrated herein may broadly represent any type or form of computing device or system capable of executing computer-readable instructions, such as those contained within the modules described herein.
  • these computing device(s) may each include at least one memory device and at least one physical processor.
  • the term “memory device” generally refers to any type or form of volatile or non-volatile storage device or medium capable of storing data and/or computer-readable instructions.
  • a memory device may store, load, and/or maintain one or more of the modules described herein. Examples of memory devices include, without limitation, random access memory (RAM), read only memory (ROM), flash memory, hard disk drives (HDDs), solid-state drives (SSDs), optical disk drives, caches, variations or combinations of one or more of the same, or any other suitable storage memory.
  • RAM random access memory
  • ROM read only memory
  • HDDs hard disk drives
  • SSDs solid-state drives
  • optical disk drives caches, variations or combinations of one or more of the same, or any other suitable storage memory.
  • the term “physical processor” generally refers to any type or form of hardware-implemented processing unit capable of interpreting and/or executing computer-readable instructions.
  • a physical processor may access and/or modify one or more modules stored in the above-described memory device.
  • Examples of physical processors include, without limitation, microprocessors, microcontrollers, central processing units (CPUs), field-programmable gate arrays (FPGAs) that implement softcore processors, application-specific integrated circuits (ASICs), portions of one or more of the same, variations or combinations of one or more of the same, or any other suitable physical processor.
  • modules may be provided as separate elements, the modules described and/or illustrated herein may represent portions of a single module or application.
  • one or more of these modules may represent one or more software applications or programs that, when executed by a computing device, may cause the computing device to perform one or more tasks.
  • one or more of the modules described and/or illustrated herein may represent modules stored and configured to run on one or more of the computing devices or systems described and/or illustrated herein.
  • One or more of these modules may also represent all or portions of one or more special-purpose computers configured to perform one or more tasks.
  • one or more of the modules described herein may transform data, physical devices, and/or representations of physical devices from one form to another.
  • one or more of the modules recited herein may receive sensor data to be transformed, transform the sensor data, output a result of the transformation to control impingement of light onto living tissue, use the result of the transformation to control impingement of light onto living tissue, and/or store the result of the transformation to control impingement of light onto living tissue.
  • one or more of the modules recited herein may transform a processor, volatile memory, non-volatile memory, and/or any other portion of a physical computing device from one form to another by executing on the computing device, storing data on the computing device, and/or otherwise interacting with the computing device.
  • the term “computer-readable medium” generally refers to any form of device, carrier, or medium capable of storing or carrying computer-readable instructions.
  • Examples of computer-readable media include, without limitation, transmission-type media, such as carrier waves, and non-transitory-type media, such as magnetic-storage media (e.g., hard disk drives, tape drives, and floppy disks), optical-storage media (e.g., compact disks (CDs), digital video disks (DVDs), and Blu-ray disks), electronic-storage media (e.g., solid-state drives and flash media), and other distribution systems.
  • transmission-type media such as carrier waves
  • non-transitory-type media such as magnetic-storage media (e.g., hard disk drives, tape drives, and floppy disks), optical-storage media (e.g., compact disks (CDs), digital video disks (DVDs), and Blu-ray disks), electronic-storage media (e.g., solid-state drives and flash media), and other distribution systems
  • servers are disclosed that are capable of sending and receiving information to and from multiple illumination devices that are in use.
  • Servers may be capable of providing functionality and/or operating instructions for illumination devices in response to received information from illumination devices and/or receiving information from illumination devices once light treatments have been implemented.
  • servers may be capable of communicating treatment protocols to illumination devices based on received diagnostic information.
  • illumination devices may be capable of communicating other information, such as location information, back to the server.
  • the server may be capable of compiling geospatial information related to timing and locations of implemented light treatments.
  • geospatial information may be beneficial in predicting outbreaks and/or for identifying regions where previously identified outbreaks are subsiding.
  • the geospatial information may further be useful in identifying specific disease strains and/or variants that may be present in a certain area based on which treatment protocols are most prevalent.
  • illumination devices and related systems for compiling geospatial information may beneficially provide precise light treatment information, or administered light treatment information, for use in evaluating various treatment protocols. For example, exact timings and dosing sequences of administered phototherapy may be captured by the system for comparison with patient outcomes.
  • illumination devices may use sensors and/or cameras to confirm precise therapeutic dosing has been delivered.
  • FIG. 1 is a schematic view of a system 10 for administering and monitoring phototherapy treatments of multiple illumination devices 12 at various geographic locations.
  • the illumination devices 12 may be separately controlled or managed by all or a portion the system 10.
  • the system 10 may include a server 14 in communication with one or more clientside or local devices 16 via a network 18.
  • One or more local devices 16 may be associated with a single illumination device 12 or with multiple illumination devices 12 that reside in a common geographic location or region.
  • Exemplary local devices 16 include, without limitation, laptops, tablets, desktops, local servers, cellular phones, personal digital assistants (PDAs), multimedia players, embedded systems, wearable devices (e.g., smart watches, smart glasses, etc.), routers, switches, gaming consoles, combinations of one or more of the same, or any other suitable computing device.
  • the local device 16 may represent a user’s computing device to which the user has paired with at least one illumination device 12.
  • the local device 16 may include a local device application 17 for managing, controlling, and/or communicating with one or more of the illumination devices 12.
  • the local device application 17 may embody an application on a computer or a mobile device, such as a phone, tablet, laptop, or wearable device, among others.
  • the local device application 17 may be configured to collect sensor data from one or more of the illumination devices 12 and/or user feedback that may be used by the server 14 and/or local device 16 to determine appropriate treatment protocols.
  • the server 14 and the illumination devices 12 may be capable of communicating without intermediate local devices 16.
  • the server 14 may include a server-side application 20 for managing, controlling, and/or communicating with the local devices 16 and/or illumination devices 12.
  • the server-side application 20 may be configured to collect usage data associated with location information of the multiple illumination devices 12.
  • the network 18 generally represents any medium or architecture capable of facilitating communication or data transfer. Examples of the network 18 include, without limitation, an intranet, a wide area network (WAN), a local area network (LAN), a personal area network (PAN), the Internet, power line communications (PLC), a cellular network (e.g., a global system for mobile communications (GSM) network), or the like.
  • the network 18 may facilitate communication or data transfer using wireless or wired connections between the server 14 and the one or more local device 16 and the illumination devices 12.
  • the server 14 may include a database 22 and/or an artificial intelligence library 24 that are populated with suitable data, including but not limited to clinical trial data and data (e.g., images and other sensor data) captured by other illumination devices in practice, that allows the server-side application 20 to receive data specific to a particular user, compare the data with the artificial intelligence library 24, and formulate a tailored phototherapy treatment protocol.
  • the artificial intelligence library 24 may be continually updated and refined based on populated data to continuously improve the ability of the server-side application 20 to provide malady detection and corresponding tailored phototherapy treatments with increased efficacy.
  • the artificial intelligence library 24 may refer to a collection of data (e.g., images and/or sensor data) that correspond to previously identified characteristics of body tissues, including but not limited to the presence of pathogens, diseases, cancerous or pre-cancerous lesions, tumors or polyps, accumulation of fluid, and inflammation, among other tissue characteristics and conditions.
  • the artificial intelligence library 24 may be utilized by the server-side application 20 and/or the local device application 17 to recognize diagnostic information received from the illumination devices 12, compare the received diagnostic information to data received from other illumination devices, and provide appropriate treatment protocols that may be administered by the illumination devices 12 for inducing any number of biological effects.
  • the system 10 may provide a method that includes accessing data related a particular user, generating at least one treatment protocol based on the data, communicating the treatment protocol to the illumination device(s) 12 associated with the user, and providing geospatial location information related to the implemented treatment protocol. Compiled geospatial location information from multiple users and multiple illumination devices may accordingly be used to provide overall geographical information.
  • FIG. 2 is a schematic view of the system 10 of FIG. 1 with further details provided for one illumination device 12. While a single illumination device 12 is represented in FIG. 2, it is understood that principles described are applicable to any of the illumination devices 12 that may be associated with the system 10.
  • the illumination device 12 may include one or more light emitters 26, a communication module 28, and a control system 30 associated with the light emitters 26 and the communication module 28.
  • the communication module 28 may facilitate communication with the local device 16 and the local device application 17.
  • the communication module 28 may also be configured to communicate directly with the server 14 by way of the network 18 and without the intermediate local device 16.
  • the communication module 28 may provide communication via any number of manners, including Bluetooth, wired and/or wireless internet connections, a cellular network, analog communication such as one or more pre-programmed buttons of the illumination device 12, or any other form of analog or digital communication.
  • the control system 30 may include emitter driving circuitry, among other control circuitry, that is configured to drive the light emitters 26 according to a treatment protocol.
  • the control system 30 may further be configured to determine location information associated with the implemented treatment protocol and send the location information to the server 14 by way of the communication module 28.
  • the illumination device 12 may include a power source 32 that includes any type of internal power source and/or connections to an external power source.
  • the power source 32 may embody a portable power source and/or an energy storage device that is provided within the illumination device 12, such as a replaceable battery and/or a rechargeable battery.
  • the illumination device 12 may include a port, (e.g., a universal serial bus port, a power plug, or the like) for providing a connection to an external power source or even another device, such as the local device 16, for recharging.
  • the port may also facilitate data transfer and communication via the communication module 28.
  • the power source 32 may be configured for direct connections to an external power source with or without recharging capabilities, including a wired and/or a plug-direct configuration to the external power source.
  • the external power source may include a hardwired electrical connection such as a wall plug or any type of wired or portable external energy storage device.
  • the external power source coupled to the power source 32 of the illumination device 12 may embody a human factor power source at the client-side that provides power responsive to human movements, such as walking and/or chewing by a user.
  • the external power source may further embody renewable energy sources, including solar and/or wind sources, that provide power to and or recharging of the power source 32.
  • the system 10 may include a solar element or panel that may be worn by a user of the illumination device 12, such as solar hat, a solar sleeve, or any other form of solar clothing.
  • the illumination device 12 may include a memory device 34 that stores various drive algorithms and/or control schemes for the control system 30 based on information, including information received from the server 14.
  • the memory device 34 may further be configured to store data and diagnostic information collected at a body tissue 36 of a user for communication with the server 14.
  • the memory device 34 may include any type or form of a volatile and/or a non-volatile storage device or any medium capable of storing data and/or computer-readable instructions.
  • the memory device 34 may include, without limitation, RAM, ROM, flash memory, HDDs, SSDs, optical disk drives, caches, and variations or combinations of one or more of the same, or any other suitable storage memory. While the control system 30, the communication module 28, and the memory device 34 are illustrated as separate blocks or elements, each of the control system 30, the communication module 28, and the memory device 34 may also embody elements within a combined overall control circuitry module for the illumination device 12.
  • the illumination device 12 may include one or more of a camera 38 and one or more sensors 40 configured for capturing images or other diagnostic information of the body tissue 36 that may be relayed back to the server 14 for analysis.
  • Captured images may include one or more visible-light images, one or more IR images, one or more UV images, one or more images measuring light within a predetermined range of wavelengths, one or more images measuring light within two or more different predetermined ranges of wavelengths, reflected resonance images, reflected wave images, and ultrasound images.
  • the sensors 40 may include one or more of temperature sensors, photo sensors, image sensors, proximity sensors, blood pressure or other pressure sensors, chemical sensors, biosensors (e.g., heart rate sensors, body temperature sensors, sensors that detect presence or concentration of chemical or biological species, or other conditions), accelerometers, moisture sensors, oximeters, such as pulse oximeters, current sensors, voltage sensors, and the like.
  • the camera 38 and sensors 40 may work together as needed to perform various functions, including identifying a location of a launch lens or plane relative to a disease location of the body tissue 36, including but not limited to various tissues, suspended mucous, hardened puss pockets, organs, and bones.
  • the camera 38 may further provide precise location information for the body tissue 36 based on camera pixelated measurements and global positioning system (GPS) data, among others.
  • GPS global positioning system
  • the camera 38 and/or sensors 40 may capture three-dimensional imaging, such as light detection and ranging (LIDAR) of one or more portions of the user, including the body tissue 36 or other body portions associated with positioning the illumination device 12 relative to the body tissue 36.
  • LIDAR light detection and ranging
  • Such three-dimensional images may be relayed back to the server 14 for determining specific and/or custom arrangements of the illumination device 12.
  • the three-dimensional images may be used to choose between various pre-configurations of the illumination device 12 as part of a treatment protocol.
  • the three-dimensional images may be used to create custom shapes for certain elements of the illumination device 12.
  • a custom mouthpiece may be generated and sent to the user for use during phototherapy in or through the oral cavity.
  • the local device 16 may be in communication with a three-dimensional printer that may create the custom mouthpiece for more immediate use.
  • the captured images and/or sensor data from the illumination device 12 and/or provided by the other tissue diagnostics 42 may be relayed to one or more of the local device 16 and/or the server 14 for analysis. Accordingly, the captured images and/or data may be compared with large volumes of photos of known diseased tissue and corresponding data that are stored in the artificial intelligence library 24.
  • the system 10 may determine characteristics of the body tissue 36 including but not limited to one or more of a name and strain of one or more pathogens that are present, a size of an impacted area of the body tissue 36, any cancerous or pre-cancerous lesions, tumors or polyps, accumulation of fluid, and inflammation.
  • the illumination device 12 may be configured to administer multiple wavelengths of light for inducing multiple biological effects, either concurrently or sequentially based on the treatment protocol. For example, the illumination device 12 may detect that an initial dose from the treatment protocol resulted in inflammation or tissue damage. Based on this information, the illumination device 12 may then provide a second dose of light at a different wavelength from the initial dose that treats tissue damage and/or reduces inflammation. In a specific example, a dose of red light could be provided to repair tissue after a dose of UV light has been provided to eliminate pathogens but may have damaged the tissue.
  • the artificial intelligence library 24 may initially be populated with as many images as possible that are then added to with each subsequent new patient data.
  • the system 10 may further provide functionality that includes determining corresponding treatment costs to provide real-time billing, appropriate insurance claims, and exchange of payments.
  • the system 10 may further be used to monitor the body tissue 36 and recommend a subsequent anti-inflammatory treatment depending on the resolution of the disease.
  • patient outcomes may continually be optimized by the server 14 based on collective information received by multiple ones of the illumination devices 12 across a large volume of different body tissues. Optimization may refer to a best-available or a continually-improved medical outcome such as one or more of prevention, treatment, cure, and follow-up treatments for one or more conditions that may be present.
  • the server 14 may further identify other recommended treatments for the body tissue 36 that may be implemented in combination with the illumination device 12, such as one or more medications that may be administered to further improve or optimize medical outcomes.
  • the treatment protocol provided by the server 14 may include any number of changeable attributes for the illumination device 12, such as one or more peak wavelengths, radiant fluxes, irradiances, exposure times, and corresponding doses that may be provided by the light emitters 26 to the body tissue 36. Treatments may be administered over any time range as previously described, including by way of example, a range of 0.05 to 360 seconds of total illumination device 12 operation per treatment or dose. Doses may be provided by a series of energy sources or alternatives of the same energy source (e.g., different peak wavelengths of light) that may be deployed in a singular or multiple fashion according to any of the previously described embodiments.
  • one or more of the light emitters 26 may provide changeable attributes from visible light sources such as one or more of LEDs, OLEDs, incandescent light sources, fluorescent light sources, liquid crystal displays, lasers, halogen sources, tungsten-halogen sources, sodium vapor sources, gas laser sources, microwave photons, biological sources such as dinoflagellates, and light that is harnessed from sunlight, including filtered and unfiltered sunlight.
  • visible light sources such as one or more of LEDs, OLEDs, incandescent light sources, fluorescent light sources, liquid crystal displays, lasers, halogen sources, tungsten-halogen sources, sodium vapor sources, gas laser sources, microwave photons, biological sources such as dinoflagellates, and light that is harnessed from sunlight, including filtered and unfiltered sunlight.
  • the one or more light emitters 26 may include light sources beyond just visible light, including but not limited to UV light sources, quick-flash UV-C light or other rapid UV emissions from any suitable UV light sources, and IR sources. While previously described embodiments have been provided in the context of various sources of light, the principles of the present disclosure are also applicable to one or more other types of directed energy sources.
  • a directed energy source may include any of the various light sources previously described, and/or an energy source capable of providing one or more of heat, IR heating, resistance heating, radio waves, microwaves, soundwaves, ultrasound waves, electromagnetic interference, and electromagnetic radiation that may be directed to the body tissue 36.
  • changeable attributes provided by the server 14 may include protocols for administering any of the directed energy sources listed above to the body tissue 36.
  • the illumination device 12 may include one or more directed energy sources capable of providing directed energy beyond visible and UV light to the body tissue 36, alone or in combination with the light emitters 26.
  • the directed energy source capable of providing directed energy beyond visible and UV light may be provided separately from the illumination device 12 while still being in communication with the server 14 in a similar manner as described for the illumination device 12.
  • the changeable attributes may also include identification of one or more combinations of optics, locators, light source positioners, and light guide positioners that may be attached or otherwise utilized by the illumination device 12 to deliver identified doses of light to different types of the body tissue 36, such as one or more tissues of the upper respiratory tract, the auditory canal, the nasal cavity, the oral cavity, the oropharyngeal area, the throat, the larynx, the pharynx, the oropharynx, the trachea, the esophagus and the like, to stimulate mucosal epithelial cells.
  • the body tissue 36 may also include tissues of one or more of the lungs and endothelial tissues.
  • the body tissue 36 may also include any subordinate areas related to respiratory diseases, including gastrointestinal tissue that processes mucous.
  • the body tissue 36 may include the skin and/or scalp of a user.
  • any of the above-described elements and functions of the system 10 may be provided with less automated configurations.
  • a more simplified version of the system 10 may include a configuration where a user may click-through a menu or simply press pre-configured buttons on the illumination device 12 and/or the local device 16 to select a particular treatment program.
  • a user may progress through one or more steps on the illumination device 12 and/or the local device 16 to provide images or other diagnostic information via the illumination device 12 or via off-the-shelf test kits or other in-office procedures.
  • one or more of the local device 16 and the illumination device 12 may also include a local artificial intelligence library so that treatment protocols may be provided without having to first communicate with the server 14.
  • the local artificial intelligence library may be periodically synchronized with the artificial intelligence library 24 of the server 14 according to routine intervals.
  • the system 10 may be well-suited for communicating implemented treatment protocols associated with geographic locations to the server 14. Accordingly, the server 14 may be capable of compiling geospatial information related to timing and locations of implemented light treatments. In the context of infectious diseases, such geospatial information may be beneficial in predicting outbreaks, identifying locations of disease variants, and/or for identifying regions where previously identified outbreaks are subsiding.
  • FIGS. 3 to 6 are call-flow diagrams illustrating various implementations of the system 10 of FIGS. 1 and 2. Each of the call-flow diagrams generally lists the illumination device(s) 12, the local device 16, and the server 14 as described above for FIGS. 1 and 2.
  • the local device 16 and the server 14 as illustrated in FIGS. 3 to 6 may form part of the overall system 10 along with any of the other above-described elements of the system 10 described above for FIGS. 1 and 2.
  • dashed line boxes may indicate optional portions of the call-flow diagram and/or different stages of the call-flow diagrams where certain steps may be performed.
  • functionality may be illustrated that is associated with one or more combinations of the illumination device(s) 12, the local device 16, and the server 14, it is understood that FIGS. 3 to 6 represent exemplary embodiments. In this manner, functionality that is shown in an associated manner with one of the illumination device(s) 12, the local device 16, or the server 14 may alternatively be implemented by a different one of the illumination device(s) 12, the local device 16, and the server 14, or combinations thereof.
  • FIG. 3 is a call-flow diagram illustrating an implementation of the system 10 of FIGS. 1 and 2 where the server 14 determines a treatment protocol for the illumination device 12 based on received diagnostic and/or user information from the illumination device 12 and/or the local device 16.
  • the illumination device 12 may collect diagnostic information (step 300) associated with a user based on imaging and/or sensor data collected by the illumination device 12 and/or other diagnostic information collected external to the illumination device 12.
  • the local device 16 may then determine location information (step 302) associated with the diagnostic information, while in other embodiments, the location information may be associated at a later step as described below.
  • the illumination device 12 may then send the diagnostic information (step 304) to the local device 16.
  • the local device 16 may associate additional information (step 306), such as a user identification (ID) with the diagnostic information. With the user ID, the local device 16 may accordingly obtain and associate other user information, such as the user’s medical history and/or the user’s demographics with the diagnostic information (step 308). The local device 16 may then send the diagnostic information and the user information to the server 14 for analysis (step 310). In other embodiments, the local device 16 may serve as a pass- through for the diagnostic information without associating the user ID.
  • ID user identification
  • the local device 16 may serve as a pass- through for the diagnostic information without associating the user ID.
  • the local device 16 may then send the treatment protocol to the illumination device 12 (step 322).
  • the illumination device 12 may then implement the treatment protocol (step 324) and send the completed treatment information along with the location information back to the server 14 (step 326).
  • completed treatment information which may also be referred to as administered light treatment information, refers to information related to actual light treatments received by a user. Such information may include dosing information, including wavelengths and/or timing of implemented light treatments.
  • administered light treatment information may be helpful for evaluating efficacy of light treatments by differentiating intended treatment protocols from light treatments that were actually administered to a user.
  • the treatment protocol received from the server 14 may be modified from a pre-configured protocol that is loaded on the illumination device 12.
  • the local device 16 may associate the location information after implementing treatment (step 328).
  • the server 14 may compile geospatial information based on received treatment, location, and user information to provide geographical information related to usages of light therapy as described above (step 330).
  • such real-time exchange of information may allow monitoring of various operating functions of the illumination device 12, such as battery or charging errors, or light output, that may trigger a software patch that may be downloaded to the illumination device 12 or even a replacement or recall of the illumination device 12.
  • the local device 16 may also associate the diagnostic information with the user ID (step 408), obtain any other user information that may be associated with the user ID (step 410), and associate the user ID with the generated treatment protocol (step 412).
  • the local device 16 may then send the treatment protocol (step 414) to the illumination device 12 for implementation (step 416). If the location information has not already been associated, the illumination device 12 may do after or concurrently with implementation (step 418).
  • the illumination device 12 may then send the completed or administered treatment information along with the location information back to the server 14 (step 420) for geospatial compiling (step 422).
  • the administered treatment information may also include one or more of the diagnostic information for a user and additional user information such as a user’s medical history and/or a user’s demographics.
  • the local device 16 may associate the location information after implementing treatment.
  • the server 14 and/or the server-side application 20 may compile geospatial information or provide geospatial information for compiling by another device that can access the geospatial information.
  • diagnostic information may be provided to the local device 16 from the user or from a health professional who has evaluated the user and collected various imaging and/or other testing information.
  • the local device 16 may associate the treatment protocol with the user ID (step 516) and determine location information associated with the treatment protocol (step 518) before sending the treatment protocol to the illumination device 12 (step 520).
  • the illumination device 12 may be configured to receive and implement treatment protocols (step 522) and optionally determine location information associated with the treatment protocol (step 524) before sending the completed treatment information and location information to the server 14 (step 526) for geospatial compiling (step 528).
  • FIG. 6 is a call-flow diagram illustrating another implementation of the system 10 of FIGS. 1 and 2 where the illumination device 12 is pre-configured with one or more treatment protocols that may be implemented.
  • the one or more pre-configured treatment protocols may be loaded or programmed with the control system 30 of the illumination device 12.
  • a user may selfadminister the pre-configured treatment protocol based on symptoms or at the recommendation of a health professional (step 600).
  • the illumination device 12 may be configured to modify the pre-configured treatment protocol based on diagnostic information collected by way of a camera and/or a sensor that is associated with the illumination device 12. After light treatments are administered, the illumination device 12 may send the administered treatment information to the local device 16 (step 602) and the server 14 (step 604).
  • Either the illumination device 12 or the local device 16 may determine the location information associated with the implemented treatment protocol (step 606 or step 608).
  • the server 14 and/or the serverside application 20 may compile geospatial information or provide geospatial information for compiling as described above (step 610).
  • various types of information are exchanged between one or more of the illumination devices 12, local devices 16, networks 18, and servers 14.
  • Such information may include diagnostic information associated with a user, location information associated with the user, additional user information including a user ID and a medical history of the user, treatment protocols, and/or location information associated with implemented treatments.
  • diagnostic information associated with a user
  • location information associated with the user additional user information including a user ID and a medical history of the user, treatment protocols, and/or location information associated with implemented treatments.
  • certain embodiments involve one or more of the illumination devices 12, local devices 16, networks 18, and servers 14 being configured to send and/or receive information that is protected by way of encryption or other protection techniques.
  • one or more of the illumination devices 12, local devices 16, networks 18, and servers 14 may be configured to send and/or receive encrypted data.
  • one or more of the illumination devices 12, local devices 16, networks 18, and servers 14 may be configured to send and/or receive information based on blockchain technology.
  • the server 14 and database 22 as illustrated in FIG. 2 may be decentralized across multiple devices according to distributed ledger technology. In this regard, sensitive information related to the user, the user’s location, and the implemented treatment protocol may be readily exchanged with enhanced digital security.
  • Illumination devices 12 for the system 10 of FIGS. 1 and 2 and for any of the call-flow diagrams illustrated in FIGS. 3 to 6 may embody various device types configured to induce various biological effects and/or promote various health-related benefits.
  • Exemplary illumination devices include those that are configured to treat infectious diseases, to stimulate growth of hair, to stimulate increased blood flow in the brain for the treatment of dementia, and/or to modulate foreign body responses in tissue.
  • FIG. 7A is a perspective view of an exemplary illumination device 44 that is configured to direct light emissions within or through a body cavity, such as the oral cavity.
  • FIG. 7B is a side view of the illumination device 44 of FIG. 7A.
  • the illumination device 44 may embody a handheld device for delivering light (e.g., nitric-oxide modulating light and/or light to induce any of the previously described biological effects) to living tissue within or near a user's oral cavity, including the oropharynx.
  • light e.g., nitric-oxide modulating light and/or light to induce any of the previously described biological effects
  • initial infection sites may be associated with tissue of the oropharynx.
  • the light guide 50 may embody a hollow light guide through with light travels, while in other embodiments, the light guide 50 may embody a material through which the light propagates.
  • the light-guide positioner 52 may be referred to as a mouthpiece for the illumination device 44.
  • a portion of the light guide 50 may form a tongue depressor 54 that is configured to depress a user's tongue when inserted into the user's mouth to provide a direct light path from the light guide 50 to the oropharynx.
  • multiple illumination devices 44 may be implemented as the illumination devices 12 in FIGS. 3 to 6.
  • infectious diseases of the upper respiratory system such as Orthomyxoviridae (e.g., influenza) and Coronaviridae (e.g., SARS-CoV-2), among others
  • different treatment protocols may be developed in the treatment of various diseases and/or strains or variants of a particular disease.
  • targeted treatment protocols may be varied for individual illumination devices 44 based on collected diagnostic information, such as sensor and/or camera data.
  • collected diagnostic data may identify a larger distance from the front of the mouth to the oropharynx based on a particular user’s anatomy.
  • a treatment protocol may be developed that increases a time and/or intensity of light emissions so the user may receive the targeted dose.
  • the collected diagnostic data may be used to determine actual dosing received by the user and reported to the server 14.
  • a treatment protocol may be developed based on a user’s symptoms and implemented by the illumination device 12.
  • the illumination device 12 may associate collected diagnostic data at the time of treatment that includes the actual distance to the oropharynx.
  • the administered light treatment information reported back to the server 14 may include an actual received dose that accounts for variations based on the user’s anatomy. With this information, the server 14 would have actual doses administered and in combination with outcomes of the user, the server 14 may be able to adjust treatment protocols for other users with increased precision.
  • the compiling of geospatial data as described above may be useful in providing early detection of regional outbreaks, based on which treatment protocols are most prevalent.
  • FIGS. 8A - 8B illustrate an exemplary illumination device 56 that is configured to provide light therapy to the scalp and/or brain of a patient to promote hair growth or to promote increased blood flow in the brain for the treatment of dementia.
  • multiple illumination devices 56 of FIG. 8A may be implemented as the illumination devices 12 in FIGS. 3 to 6.
  • the compiling of geospatial data as described above may be useful in providing regional demographics based on what treatment protocols are most used and/or of greatest interest.
  • FIG. 8A is an exploded view of the illumination device 56 embodied as a wearable cap for delivering phototherapy to a scalp and/or brain of a user.
  • the illumination device 56 may include multiple light emitters and standoffs supported by a flexible printed circuit board (FPCB) 58 including multiple interconnected panels 60A-60F arranged in a concave configuration.
  • a concave shaping member 62 (including a frame 64, ribs 66A-66C, and curved panels 68A-68B) is configured to receive the FPCB 58.
  • the ribs 66A-66C and curved panels 68A- 68B project generally outwardly and downwardly from the frame 64.
  • Gaps are provided between portions of adjacent ribs 66A-66C and curved panels 68A-68B to accommodate outward expansion and inward contraction, and to enable transfer of heat and/or fluid (e.g., evaporation of sweat).
  • a fabric covering element 70 is configured to cover the concave shaping member 62 and the FPCB 58 contained therein.
  • a battery 72 and a battery holder 74 are arranged between the FPCB 58 and the concave shaping member 62.
  • An electronics housing 76 is arranged to be received within an opening 78 defined in the frame 64 of the concave shaping member 62.
  • Pivotal coupling elements 80, 82 are arranged to pivotally couple the battery holder 74 to the electronics housing 76.
  • An electronics board 84 is insertable into the electronics housing 76, which is enclosed with a cover 86.
  • Various elements may be arranged on the electronics board 84, such as a cycle counter 88, a control button 90, a charging/data port 92, and a status lamp 94.
  • the various elements associated with the electronics housing 76 and the electronics board 84 may be referred to generally as a “control module.”
  • Windows 96 may be defined in the cover 86 to provide access to the cycle counter 88, the control button 90, the charging/data port 92, and the status lamp 94.
  • the fabric covering element 70 includes a fabric body 98 and multiple internal pockets 100A-100B arranged to receive portions of the ribs 66A- 66C. An opening 102 at the top of the fabric covering element 70 is arranged to receive the cover 86.
  • FIG. 8B is a bottom plan view of the FPCB 58 of FIG. 8A illustrating light emitters 104 and standoffs 106 arranged thereon.
  • the FPCB 58 may include a polyimide substrate 107 with an inner surface 107A configured to conform in a concave shape.
  • the light emitters 104 may include a total of 280 LEDs arranged as 56 strings of 5 LEDs, with a string voltage of 11 volts (V), a current limit of 5 milliampere (mA), and a power consumption of 3.08 watts (W).
  • FIG. 8B illustrates 36 standoffs 106 extending from the inner surface 107A of the FPCB 58.
  • the FPCB 58 may include six interconnected panels 60A-60F, with the panels 60A-60F being connected to one another via narrowed tab regions. Gaps are formed between various panels 60A- 60F to allow the FPCB 58 to conform in the shape of a user’s head and to permit transport of heat and/or fluid (e.g., evaporation of sweat) between the panels 60A-60F.
  • heat and/or fluid e.g., evaporation of sweat
  • FIGS. 9 and 10 illustrate exemplary illumination devices 108-1 and 108-2 that may embody devices with probes and/or needles that remain in tissue for periods of time, such as continuous glucose monitors (CGMs).
  • CGMs continuous glucose monitors
  • multiple illumination devices 108-1 , 108- 2 may be implemented as the illumination devices 12 in FIGS. 3 to 6 to provide geospatial information as described above.
  • FIG. 9 is an illustration representing a CGM 108-1 with an incorporated light source 110 capable of delivering FBR-modulating light to a host's skin 112 during monitoring.
  • the light source 1 10 may embody any of the light emitters 26 as previously described for FIG. 2.
  • the CGM 108-1 may generally include a sensor holder 114 that includes a sensor probe 1 16.
  • the sensor holder 114 may mechanically support the sensor probe 1 16 during percutaneous insertion.
  • the sensor probe 116 may be provided in a perpendicular manner relative to the CGM 108-1 .
  • the sensor probe 1 16 may be provided at an angle relative to the CGM 108-1 .
  • the sensor holder 1 14 is typically secured to the skin 112 by way of an adhesive.
  • the CGM 108-1 may further include a transmitter 1 18 capable of relaying glucose sensing information to an external device, such as one or more of a portable monitor, a cell phone, a wearable device (e.g., a watch or other graphical display device), a computer, and a network.
  • the external device may embody one or more of the local device 16 and the server 14 of FIGS. 1 and 2.
  • the transmitter 1 18 may include one or more of a power source (e.g., a battery or rechargeable battery), a microprocessor and/or microcontroller, a communications module (e.g., 28 of FIG.
  • the CGM 108-1 may further include an optional insulin infusion catheter 120.
  • an associated insulin infusion catheter may be provided separately from the CGM 108-1.
  • one or more light sources 1 10 may be provided within the sensor holder 1 14 in an arrangement that provides light to areas of the skin 1 12 at or near the injection site of the sensor probe 116. Such an arrangement may be suitable for providing light to modulate the FBR at the injection site and depending on the wavelength, to depths beneath the skin 1 12 that correspond with tissue regions that include the sensor probe 116.
  • FIG. 10 is an illustration representing a CGM 108-2 that is similar to the CGM 108-1 of FIG. 9 and further includes a corresponding light delivery structure 122 capable of delivering FBR-modulating light beneath the host's skin 1 12 during monitoring.
  • the light delivery structure 122 may embody an optical waveguide, such as a fiber optic, that receives light from at least one of the light sources 1 10 in the CGM 108-2.
  • the light source 1 10 may reside within the sensor holder 1 14 and the light delivery structure 122 may be mechanically supported by the sensor holder 114. Accordingly, the sensor probe 1 16 and the light delivery structure 122 may be concurrently inserted beneath the skin 112.
  • the light delivery structure 122 may be suitable for delivering light along portions of the sensor probe 116 in order to modulate the FBR and improve accuracy of the sensor probe 1 16 over time.
  • treatment protocols may be developed and administered by illumination devices based on diagnostic information specific to a patient in combination with global diagnostic information and efficacy of previously administered treatment protocols.
  • the server may analyze and compare patient-specific information with global information to generate tailored treatment protocols. Delivery of the tailored treatment protocols may be provided to the illumination device and/or to a medical provider that may administer the treatment. Since the illumination device is in communication with the server, information may be exchanged while a treatment is being administered to provide real-time monitoring and/or adjustments to treatments.
  • such realtime adjustments may allow a patient to receive suitable treatments with reduced treatment time and with reduced side-effects.
  • the server may continuously receive and analyze global treatment information to continuously fine tune the next generated treatment protocols.
  • the server and associated synthetic intelligence may be well suited for determining a disease state or other condition of a patient and providing a tailored treatment protocol based on the most up to date information possible.
  • systems of the present disclosure may also have manual functions where designated or authorized personnel can update diagnostic information and/or databases or artificial intelligence libraries. While the information is being exchanged and compiled, the server may also be capable of monitoring patient habits and/or compliance with treatment protocols and providing diagnostics related to operation of the illumination devices.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Des dispositifs et des systèmes destinés à assurer l'incidence d'une lumière sur un tissu pour induire un ou plusieurs effets biologiques et, plus particulièrement, des dispositifs d'éclairage et des systèmes associés destinés à mettre en œuvre des traitements thérapeutiques de lumière sont divulgués. Les systèmes peuvent comprendre des dispositifs d'éclairage qui sont configurés pour fournir une luminothérapie pour une variété d'indications médicales et/ou d'effets bénéfiques sur la santé. Des dispositifs d'éclairage peuvent être reliés à des systèmes qui administrent et/ou surveillent de multiples dispositifs d'éclairage à travers de multiples régions géographiques pour compiler des informations régionales et/ou mondiales relatives à l'utilisation de la luminothérapie. Certains aspects concernent des éléments de système, tels que des dispositifs locaux et/ou des serveurs qui permettent de générer des protocoles de traitement pour des dispositifs d'éclairage sur la base d'informations de diagnostic. Après que des protocoles de traitement sont mis en œuvre par des dispositifs d'éclairage, des informations de traitement administré avec des informations d'emplacement peuvent être fournies aux dispositifs locaux et/ou aux serveurs.
PCT/US2023/015757 2022-03-23 2023-03-21 Dispositifs et systèmes destinés à mettre en œuvre des traitements thérapeutiques de lumière Ceased WO2023183295A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/656,141 2022-03-23
US17/656,141 US20220212031A1 (en) 2020-03-19 2022-03-23 Devices and systems for implementing therapeutic treatments of light

Publications (1)

Publication Number Publication Date
WO2023183295A1 true WO2023183295A1 (fr) 2023-09-28

Family

ID=86052453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/015757 Ceased WO2023183295A1 (fr) 2022-03-23 2023-03-21 Dispositifs et systèmes destinés à mettre en œuvre des traitements thérapeutiques de lumière

Country Status (1)

Country Link
WO (1) WO2023183295A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117462853A (zh) * 2023-10-13 2024-01-30 哈尔滨海鸿基业科技发展有限公司 一种应用于阿尔茨海默治疗的光电混合能量发生器

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105664367A (zh) * 2016-01-11 2016-06-15 苏州新索医疗设备有限公司 一种光疗仪器
US20180014777A1 (en) * 2015-06-15 2018-01-18 Haim Amir Systems and methods for adaptive skin treatment
CN108371756A (zh) * 2018-02-10 2018-08-07 中国医学科学院生物医学工程研究所 一种诊疗一体宫颈病变光动力治疗系统
KR20190063041A (ko) * 2017-11-29 2019-06-07 장현재 파장가변형엘이디마스크를 이용한 셀프광테라피앱 플랫폼 시스템
WO2020006048A1 (fr) * 2018-06-27 2020-01-02 Cala Health, Inc. Stimulation multimodale de traitement des tremblements
US20220212031A1 (en) * 2020-03-19 2022-07-07 Know Bio, Llc Devices and systems for implementing therapeutic treatments of light

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180014777A1 (en) * 2015-06-15 2018-01-18 Haim Amir Systems and methods for adaptive skin treatment
CN105664367A (zh) * 2016-01-11 2016-06-15 苏州新索医疗设备有限公司 一种光疗仪器
KR20190063041A (ko) * 2017-11-29 2019-06-07 장현재 파장가변형엘이디마스크를 이용한 셀프광테라피앱 플랫폼 시스템
CN108371756A (zh) * 2018-02-10 2018-08-07 中国医学科学院生物医学工程研究所 一种诊疗一体宫颈病变光动力治疗系统
WO2020006048A1 (fr) * 2018-06-27 2020-01-02 Cala Health, Inc. Stimulation multimodale de traitement des tremblements
US20220212031A1 (en) * 2020-03-19 2022-07-07 Know Bio, Llc Devices and systems for implementing therapeutic treatments of light

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117462853A (zh) * 2023-10-13 2024-01-30 哈尔滨海鸿基业科技发展有限公司 一种应用于阿尔茨海默治疗的光电混合能量发生器
CN117462853B (zh) * 2023-10-13 2024-04-26 哈尔滨海鸿基业科技发展有限公司 一种应用于阿尔茨海默治疗的光电混合能量发生器

Similar Documents

Publication Publication Date Title
US20220212031A1 (en) Devices and systems for implementing therapeutic treatments of light
ES2995019T3 (en) Microcurrent-stimulation-therapy apparatus
US11464996B2 (en) Capsule phototherapy
JP5654482B2 (ja) 光線療法を施すためのシステム及び方法
EP2229980B1 (fr) Traitement de pathogènes microbiologiques dans un ongle d'orteil au moyen de lumière antimicrobienne
US20100100160A1 (en) Methods and devices for self adjusting phototherapeutic intervention
US10441808B2 (en) Methods and devices for activating brown adipose tissue with light
US20120310307A1 (en) Treatment of fungal infection by light irradiation
US10744341B2 (en) System and method for directing light into a patients eye
CN105263575A (zh) 用于对大脑的无创神经刺激治疗的可自我管理的方法、系统和设备
US20220409919A1 (en) Post cecum phototherapy
WO2023183295A1 (fr) Dispositifs et systèmes destinés à mettre en œuvre des traitements thérapeutiques de lumière
Kim et al. Bioelectronic devices for light-based diagnostics and therapies
Wang et al. Challenges and opportunities in next-generation LED therapeutic devices
JP7712799B2 (ja) 薬物配送装置及びその動作方法
US20230218923A1 (en) Photodynamic antimicrobial therapy device
US12115384B2 (en) Devices and methods for illuminating tissue to induce biological effects
Smith General principles of laser therapy
US20250099776A1 (en) Phototherapeutic illumination devices with modular structures
Korotkov et al. Human Energetic Light System
CN209475403U (zh) 光动力治疗仪器的结构
CN115768515A (zh) 辐射治疗设备
US20230043538A1 (en) Illumination devices and related methods for phototherapeutic light treatments in the presence of vitamins
WO2025240212A1 (fr) Dispositifs d'éclairage photothérapeutiques à capture de données
TW202041243A (zh) 成癮症放射治療系統

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23717707

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23717707

Country of ref document: EP

Kind code of ref document: A1